Skip to content

Visomitin

Also called SkQ1, Skulachev ions, plastoquinonyl decyltriphenylphosphonium, MitoVitan, MitoVitan Active, Exomitin, the same active in an eye drop and in three topicals

A plastoquinone head group tethered by a ten-carbon chain to a triphenylphosphonium cation.

  • TypeBioregulator
  • FormTopical
  • Researched forLongevity

Where to get Visomitin

RUPharma
Topical
Code CAMERON

Sold as the form named. Approved uses are on its label; the research here goes beyond them.

Shop topical at RUPharma

The short version

  • Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
  • What the evidence isA published phase 2 safety and efficacy trial of SkQ1 ophthalmic solution in dry eye, run both in the ordinary environment and under a Controlled Adverse Environment challenge (Petrov 2016) — the methodology the US regulatory pathway for dry eye actually uses.
  • What to watchEye pain, redness or swelling.

How Visomitin works

The delivery system is the invention, and it runs on physics rather than on biology. SkQ1 is a plastoquinone head group joined by a ten-carbon linker to a triphenylphosphonium cation.

What the head group does once it is there. Plastoquinone is the electron carrier plants use in photosynthesis, and in this context it acts as a chain-breaking antioxidant inside the lipid phase of the membrane it has concentrated into. Lipid peroxidation propagates through membranes as a radical chain; an antioxidant dissolved in water cannot reach it, which is the design problem the cation solves.

The cation is the delivery mechanism and it is the whole idea: a lipophilic positive charge is driven across membranes by the electrical potential they carry, and the mitochondrial inner membrane carries the largest potential in the cell, so the molecule accumulates there by electrophoresis rather than by any receptor. The plastoquinone then does what it does in a chloroplast — intercepts the lipid peroxidation chain in the membrane it is sitting in. Concentration is the whole safety argument, because the same charge that concentrates it will uncouple respiration if there is too much of it.

  • Topical

On the goal map: Glycation, oxidation & protein damage (Longevity & healthspan)

Research on Visomitin8 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: Registered in Russia as an eye drop — the only registered SkQ1 medicine anywhere. One published phase 2 trial in dry eye. Not FDA-approved.

Human clinical evidence

  • A published phase 2 safety and efficacy trial of SkQ1 ophthalmic solution in dry eye, run both in the ordinary environment and under a Controlled Adverse Environment challenge (Petrov 2016) — the methodology the US regulatory pathway for dry eye actually uses.

  • No SkQ1 product holds a United States approval (Valdes-Arias 2024). The Russian registration is real and it is a different standard.

Correlative data

  • SkQ1 protected cornea against oxidative damage from ultraviolet irradiation and mechanical injury in animals (Zernii 2018) — local delivery to the surface it was applied to.

  • A clean negative, published with Skulachev on the author list: SkQ1 and MitoTEMPO failed to exert a long-term beneficial effect in murine polymicrobial sepsis (Rademann 2017).

  • The most recent extension away from the eye is osteoclast metabolism and bone loss through a STAT3/LDHB axis (Yuan 2025) — mechanistic animal and cell work, not a human result.

How the mechanism reads

  • The delivery mechanism is physics rather than biology: a lipophilic cation is driven into mitochondria by the membrane potential, roughly 150-180 mV negative inside, which predicts several hundred-fold accumulation with no receptor involved.

    Mechanistic
  • The same charge is the toxicity. Above its useful range the molecule uncouples the mitochondria it concentrates into, which is why the registered ophthalmic strength is 0.155 mcg/mL (0.0000155%).

    Mechanistic
  • The serum and hydrogel sold at the same price have no controlled human trial of any kind. What the phase 2 established, it established for an eye drop in an eye.

    Mechanistic

Sources

Visomitin safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Eye infection, injury or a contact lens that is irritating: use the drop only on a healthy eye.
  • Pregnancy or breastfeeding: only the registered Russian eye drop has any human data.
  • Wanting an oral or injected version: those forms are not the registered medicine.
  • Allergy to triphenylphosphonium compounds.

What’s expected

  • Brief stinging after the drop.
  • Less dry-eye discomfort, per one phase 2 trial.
  • Antioxidant action concentrated inside mitochondria; at high exposure it can act the other way.

Watch for

  • Eye pain, redness or swelling.
  • Blurred vision that does not clear.
  • Light sensitivity.
  • Hives while using Visomitin.

Labs that tell you it’s working

  • F2-Isoprostane/Creatinine (Urine)
  • Coenzyme Q10
  • hs-CRP (C-Reactive Protein, High Sensitivity)

SkQ1 ties plastoquinone to a triphenylphosphonium cation that accumulates in mitochondria; oxidative stress markers test the antioxidant claim. PMID 26733410

Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON

Visomitin FAQ4 common questions

Is Visomitin approved for human use?
Visomitin is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
What is Visomitin researched for?
Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Which labs show whether it's doing anything?
F2-Isoprostane/Creatinine; Coenzyme Q10; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Visomitin: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Visomitin is. Skool covers how it is run.

Free on this page

What Visomitin is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Visomitin is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool